An alternative approach to a frequently used nerve block in patients with a broken hip in the emergency department

Recruitment status No longer recruiting	Prospectively registered		
	☐ Protocol		
Overall study status	Statistical analysis plan		
Completed	[X] Results		
Condition category	Individual participant data		
	No longer recruiting Overall study status Completed		

Plain English summary of protocol

Background and study aims

A hip fracture is where there is a break in the upper thigh bone (femur). They are very common, particularly in older adults, and are extremely painful. A nerve block is a type of treatment in which a local anaesthetic (numbing) fluid is injected into the area that is painful in order to relieve pain. A Fascia Iliaca Compartment Block (FICB) is a type of nerve block in which the anaesthetic is injected into the space below the layer of muscle at the top of the leg. This study evaluates whether the use of a relative new way of administering this injection called a suprainguinal FICB. This is where the anaesthetic is injected above the inguinal ligament (band of tissue in the groin) in order to decrease the need for morphine-like pain medications.

Who can participate? Adults with a broken hip.

What does the study involve?

All participants receive pain management treatment with a supra-inguinal FICB. Each participant is asked to rate their pain with a number on a scale of 0 (no pain) to 10 (most severe pain imaginable) before the injection and then 30, 60 and 120 minutes afterwards. Participants are assessed and reviewed by the medical staff so that their need for other pain medication (and what they had already been given), side effects and type of hip fracture can be recorded. Data from these patients is compared with data from the hip fracture patients who do not receive this nerve block, during the same study period.

What are the possible benefits and risks of participating? There are no direct benefits or risks involved with participating, as the study does not change the treatment participants receive as part of their standard care.

Where is the study run from?
Academic Medical Center (Netherlands)

When is the study starting and how long is it expected to run for? January 2014 to July 2015

Who is funding the study?
Academic Medical Center (Netherlands)

Who is the main contact? Mr Milan Ridderikhof m.l.ridderikhof@amc.uva.nl

Contact information

Type(s)

Scientific

Contact name

Mr Milan Ridderikhof

ORCID ID

https://orcid.org/0000-0002-1561-7252

Contact details

Academic Medical Center Meibergdreef 9 Amsterdam Netherlands 1105 AZ +31 20 5663336 m.l.ridderikhof@amc.uva.nl

Additional identifiers

Protocol serial number

SuprainguinalFICB14

Study information

Scientific Title

Opioid consumption in a supra-inguinal fascia iliaca compartment block compared to systemic analgesia in Emergency Department hip fracture patients, a cohort study

Study objectives

Hypothesis as of 03/04/2017:

Administration of a supra-inguinal FICB would lead to a significant decrease in usage of opioid analgesics in elderly hip fracture patients, compared to systemic analgesia.

Original hypothesis:

Administration of the supra-inguinal FICB would cause a significant reduction in NRS pain scores.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Institutional Review Board (IRB) of the AMC waived the need for official ethics approval as the Medical Research Involving Human Subjects Act (WMO) does not apply to the study.

Study design

Prospective observational cohort study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hip fracture

Interventions

Each patient will receive care as usual, which is pain treatment using a (supra-inguinal) FICB. NRS pain scores will be followed-up strictly and asked for at baseline, as well as 30, 60 and 120 in minutes after administration of the FICB while in rest and with careful movement of the injured extremity. Patients will be questioned whether they experience any adverse events, while continuous three-lead monitoring and pulsoxymetry is continued. Patients will be asked at each NRS-pain question whether they would like additional analgesia as well. Observation and follow-up ends at the moment of discharge from the Emergency Department. Patients will receive hip fracture care as usual (admittance and surgery).

Added 03/04/2017:

Data from the remaining hip fracture patients will be collected retrospectively from the electronic patient charts.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Number of participants with a three-point decrease in Numerical Rating Scale (NRS) pain scores is measured prospectively for the FICB group at 30, 60 and 120 minutes after performing the nerve block and retrospectively from patient charts for those in the control group.

Key secondary outcome(s))

- 1. Decrease in Numerical Rating Scale (NRS) pain scores for different fracture types is measured at 30, 60 and 120 minutes after administration of the FICB for the FICB group and retrospectively from patient charts for those in the control group
- 2. Need for additional opioid analgesics is measured by emergency department and anesthesiology staff members, as well as members of the research team at 30, 60 and 120 minutes for the FICB group and retrospectively from patient charts for those in the control group
- 3. Occurrence of side effects is measured by emergency department and anesthesiology staff members, as well as members of the research team at 30, 60 and 120 minutes for the FICB group and retrospectively from patient charts for those in the control group

Completion date

31/07/2015

Eligibility

Key inclusion criteria

- 1. Adult (18 years or older) patients
- 2. Radiologically confirmed hip fracture

Removed 03/04/2017:

3. Will be treated with a supra-inguinal FICB in the ED

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

- 1. Allergies for local anesthetics
- 2. Polytrauma patients
- 3. Not receiving a supra-inguinal FICB

Date of first enrolment

01/05/2014

Date of final enrolment

30/03/2015

Locations

Countries of recruitment

Netherlands

Study participating centre Academic Medical Center

Meibergdreef 9

Sponsor information

Organisation

Academic Medical Center

ROR

https://ror.org/03t4gr691

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Academic Medical Center

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2020	Yes	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/2025	No	Yes